SOPH Valuation

Sophia Genetics SA

Add to Watchlist

Advanced Chart

3.610

0(0.000%)1D

Overview
Forecast
Valuation
Earnings

SOPH Relative Valuation

SOPH's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, SOPH is overvalued; if below, it's undervalued.

Historical Valuation

Sophia Genetics SA (SOPH) is now in the Fair zone, suggesting that its current forward PS ratio of 2.97 is considered Fairly compared with the five-year average of -4.69. The fair price of Sophia Genetics SA (SOPH) is between 0.70 to 12.92 according to relative valuation methord.

Relative Value

Fair Zone

0.70-12.92

Current Price：3.61

Fair

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

2.82

P/B

Median3y

1.71

Median5y

2.33

-17.05

FCF Yield

Median3y

-25.78

Median5y

-22.38

Competitors Valuation Multiple

The average P/S ratio for SOPH's competitors is 2.10, providing a benchmark for relative valuation. Sophia Genetics SA Corp (SOPH) exhibits a P/S ratio of 2.97, which is 41.29% above the industry average. Given its robust revenue growth of 12.68%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap